Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEPHROS INCNEPH · Entity 7279 | Director | January 01, 2025 | January 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEPHROS INC
Report date January 01, 2025 · Filed January 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 · Expires 2035-01-01 | Direct | 7,050 |
Reported balance
After 2025-01-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-01-01 · Grant · Acquired 7,050 · Balance 7,050 F4: Represents options granted to the reporting person for his service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2032-09-06 | Direct | 13,115 |
Reported balance
Holding disclosure · report date 2025-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 13,115 F1: Fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2033-01-05 | Direct | 7,080 |
Reported balance
Holding disclosure · report date 2025-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 7,080 F2: This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2034-05-14 | Direct | 7,323 |
Reported balance
Holding disclosure · report date 2025-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 7,323 F3: This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26. |
| Common StockSEC Table I · non-derivative | Direct | 17,693 |
Reported balance
Holding disclosure · report date 2025-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 17,693 |
Filing footnotes · ownership attribution and instrument terms
F1: Fully exercisable.
F2: This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25.
F3: This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.
F4: Represents options granted to the reporting person for his service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2025 Filed Jan 3, 2025 22:07 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 7,050 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001062993-25-000235 · form4.xml · derivative · entry 5 Harris Joseph Michael · CIK 0001946070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,050 Underlying: Common Stock · 7,050 shares Expires 2035-01-01 F4 · derivative.exercise_date: Represents options granted to the reporting person for his service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:23 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 7,323 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001062993-24-010451 · form4.xml · derivative · entry 4 Harris Joseph Michael · CIK 0001946070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,323 Underlying: Common Stock · 7,323 shares Expires 2034-05-14 F3 · derivative.exercise_date: Represents options granted to the reporting person for his service on the Company's Board of Directors for 2023. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 21:48 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 9,291 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022643 · form4.xml · nonDerivative · entry 1 Harris Joseph Michael · CIK 0001946070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,693 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2023. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:30 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 7,080 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001062993-23-000717 · form4.xml · derivative · entry 3 Harris Joseph Michael · CIK 0001946070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,080 Underlying: Common Stock · 7,080 shares Expires 2033-01-05 F3 · derivative.exercise_date: Represents options granted to the reporting person for his service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25. F3 · ownership.direct: Represents options granted to the reporting person for his service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:30 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 8,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-000717 · form4.xml · nonDerivative · entry 1 Harris Joseph Michael · CIK 0001946070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,402 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date. F1 · ownership.direct: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:55 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 13,115 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001437749-22-022068 · rdgdoc.xml · derivative · entry 1 Harris Joseph Michael · CIK 0001946070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,115 Underlying: Common Stock · 13,115 shares Expires 2032-09-06 F1 · derivative.exercise_date: On September 6, 2022, the Company granted to Mr. Harris an option to purchase 13,115 shares of common stock of the Company, of which one-third vested immediately upon the grant date, one-third will vest on the first anniversary of the grant date, and the remaining one-third will vest on the second anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.